Literature DB >> 27725847

Inhibition of osteopontin reduce the cardiac myofibrosis in dilated cardiomyopathy via focal adhesion kinase mediated signaling pathway.

Hui Zhao1, Wei Wang1, Jie Zhang1, Tuo Liang1, Guang-Pu Fan1, Zhi-Wei Wang1, Pei-De Zhang1, Xu Wang1, Jing Zhang1.   

Abstract

BACKGROUND: Osteopontin (OPN) is a pleiotropic cytokine, which has been shown to a close relationship with cardiac fibrosis. Overexpression of OPN in cardiomyocytes induces dilated cardiomyopathy (DCM). This research is to study whether inhibition of OPN could reduce myocardial remodelling in DCM, and if this process is focal adhesion kinase (FAK) dependent, which is recently found an important signal molecule in fibrosis.
METHOD: Eight-week-old cTnTR141W transgenic mouse of DCM were injected with OPN-shRNA in left ventricular free wall, which could inhibit the OPN expression. Six weeks later, echocardiographic examinations were performed to test left ventricle function and heart tissues were harvested to test the quality of FAK by western blot and severity of fibrosis by masson staining. Human cardiac fibroblast was administrated with OPN, and FAK inhibition by PP2 was treated 2 h before OPN was given. Expression of α-SMA and collagen-I were tested by western blot and real-time PCR assay.
RESULTS: OPN-shRNA group has a relatively high ejection fraction (EF), fractional shortening (FS), LV free wall thickness and a less sever cardiac fibrosis. In vitro, OPN could increase collagen-I and α-SMA expression, and this process can be inhibited by FAK inhibitor.
CONCLUSION: Inhibition of OPN could reduce the LV remodeling and dysfunction in DCM mice, which may attribute to the suppression of collagen-I secretion in fibroblast through a FAK/Akt dependent pathway.

Entities:  

Keywords:  Osteopontin (OPN); cardiac fibrosis; dilated cardiomyopathy (DCM); fibroblast; focal adhesion kinase (FAK)

Year:  2016        PMID: 27725847      PMCID: PMC5040665     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  32 in total

Review 1.  Focal adhesion kinase -- the basis of local hypertrophic signaling domains.

Authors:  K G Franchini
Journal:  J Mol Cell Cardiol       Date:  2011-07-02       Impact factor: 5.000

2.  Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence.

Authors:  A Oldberg; A Franzén; D Heinegård
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

3.  Increased myocardial expression of osteopontin in patients with advanced heart failure.

Authors:  Philipp Stawowy; Florian Blaschke; Peter Pfautsch; Stephan Goetze; Frank Lippek; Brigitte Wollert-Wulf; Eckart Fleck; Kristof Graf
Journal:  Eur J Heart Fail       Date:  2002-03       Impact factor: 15.534

Review 4.  Cardiac fibroblasts: from development to heart failure.

Authors:  Thomas Moore-Morris; Nuno Guimarães-Camboa; Katherine E Yutzey; Michel Pucéat; Sylvia M Evans
Journal:  J Mol Med (Berl)       Date:  2015-07-14       Impact factor: 4.599

Review 5.  Targeting focal adhesion kinase in fibrotic diseases.

Authors:  David Lagares; Mohit Kapoor
Journal:  BioDrugs       Date:  2013-02       Impact factor: 5.807

6.  Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure.

Authors:  Philip M Mottram; Brian Haluska; Rodel Leano; Diane Cowley; Michael Stowasser; Thomas H Marwick
Journal:  Circulation       Date:  2004-07-26       Impact factor: 29.690

7.  Macrophages express osteopontin during repair of myocardial necrosis.

Authors:  C E Murry; C M Giachelli; S M Schwartz; R Vracko
Journal:  Am J Pathol       Date:  1994-12       Impact factor: 4.307

8.  Structural basis of end-stage failure in ischemic cardiomyopathy in humans.

Authors:  C A Beltrami; N Finato; M Rocco; G A Feruglio; C Puricelli; E Cigola; F Quaini; E H Sonnenblick; G Olivetti; P Anversa
Journal:  Circulation       Date:  1994-01       Impact factor: 29.690

9.  Functional and structural abnormalities in patients with dilated cardiomyopathy.

Authors:  A S Bortone; O M Hess; A Chiddo; A Gaglione; N Locuratolo; G Caruso; P Rizzon
Journal:  J Am Coll Cardiol       Date:  1989-09       Impact factor: 24.094

10.  Osteopontin, a new prognostic biomarker in patients with chronic heart failure.

Authors:  Mark Rosenberg; Christian Zugck; Manfred Nelles; Claus Juenger; Derk Frank; Andrew Remppis; Evangelos Giannitsis; Hugo A Katus; Norbert Frey
Journal:  Circ Heart Fail       Date:  2008-05       Impact factor: 8.790

View more
  6 in total

1.  Systemic mesalazine treatment prevents spontaneous skin fibrosis in PLK2-deficient mice.

Authors:  Manja Newe; Theresa A Kant; Maximilian Hoffmann; Johanna S E Rausch; Luise Winter; Karolina Künzel; Erik Klapproth; Claudia Günther; Stephan R Künzel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-08-19       Impact factor: 3.195

2.  Osteopontin RNA aptamer can prevent and reverse pressure overload-induced heart failure.

Authors:  Jihe Li; Keyvan Yousefi; Wen Ding; Jayanti Singh; Lina A Shehadeh
Journal:  Cardiovasc Res       Date:  2017-05-01       Impact factor: 10.787

Review 3.  Emerging Roles of Matricellular Proteins in Systemic Sclerosis.

Authors:  Daniel Feng; Casimiro Gerarduzzi
Journal:  Int J Mol Sci       Date:  2020-07-06       Impact factor: 5.923

Review 4.  Clinical and Molecular Implications of Osteopontin in Heart Failure.

Authors:  Argen Mamazhakypov; Meerim Sartmyrzaeva; Akpay Sh Sarybaev; Ralph Schermuly; Akylbek Sydykov
Journal:  Curr Issues Mol Biol       Date:  2022-08-11       Impact factor: 2.976

5.  Syndecan-4 Protects the Heart From the Profibrotic Effects of Thrombin-Cleaved Osteopontin.

Authors:  Kate M Herum; Andreas Romaine; Ariel Wang; Arne Olav Melleby; Mari E Strand; Julian Pacheco; Bjørn Braathen; Pontus Dunér; Theis Tønnessen; Ida G Lunde; Ivar Sjaastad; Cord Brakebusch; Andrew D McCulloch; Maria F Gomez; Cathrine R Carlson; Geir Christensen
Journal:  J Am Heart Assoc       Date:  2020-01-31       Impact factor: 5.501

6.  Downregulation of Cypher induces apoptosis in cardiomyocytes via Akt/p38 MAPK signaling pathway.

Authors:  Tianming Xuan; Dongfei Wang; Jialan Lv; Zhicheng Pan; Juan Fang; Yin Xiang; Hongqiang Cheng; Xingxiang Wang; Xiaogang Guo
Journal:  Int J Med Sci       Date:  2020-08-27       Impact factor: 3.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.